About: Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters
Creator	Azizi, Ali Diaz-Mitoma, Francisco Ghorbani, Masoud Gee, Katrina Anderson, David
source	Medline; PMC
abstract	BACKGROUND: One of the major obstacles in the design of an effective vaccine against HIV-1 is the hypervariability of the HIV-1 envelope glycoprotein. Most HIV-1 vaccine candidates have utilized envelope glycoprotein from a single virus isolate, but to date, none of them elicited broadly reactive humoral immunity. Herein, we hypothesised that a cocktail of HIV-1 gp120 proteins containing multiple epitopes may increase the breadth of immune responses against HIV-1. We compared and evaluated the immunogenicity of HIV-1 vaccines containing either gp120 protein alone or in combinations of four or fourteen gp120s from different primary HIV-1 isolates in immunized hamsters. RESULTS: We amplified and characterized 14 different gp120s from primary subtype B isolates with both syncytium and non-syncytium inducing properties, and expressed the proteins in Chinese Hamster Ovary (CHO) cell lines. Purified proteins were used either alone or in combinations of four or fourteen different gp120s to vaccinate golden hamsters. The polyvalent vaccine showed higher antibody titers to HIV-1 subtype B isolates MN and SF162 compared to the groups that received one or four gp120 proteins. However, the polyvalent vaccine was not able to show higher neutralizing antibody responses against HIV-1 primary isolates. Interestingly, the polyvalent vaccine group had the highest proliferative immune responses and showed a substantial proportion of cross-subtype CD4 reactivity to HIV-1 subtypes B, C, and A/E CONCLUSION: Although the polyvalent approach achieved only a modest increase in the breadth of humoral and cellular immunity, the qualitative change in the vaccine (14 vs. 1 gp120) resulted in a quantitative improvement in vaccine-induced immunity.
has issue date	2006-10-31(xsd:dateTime)
bibo:doi	10.1186/1471-2172-7-25
bibo:pmid	17076905
has license	cc-by
sha1sum (hex)	0491da5ae5c2fa38824350bde5462ed82ebc24e7
schema:url	https://doi.org/10.1186/1471-2172-7-25
resource representing a document's title	Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters
has PubMed Central identifier	PMC1636068
has PubMed identifier	17076905
schema:publication	BMC Immunol
resource representing a document's body	covid:0491da5ae5c2fa38824350bde5462ed82ebc24e7#body_text
is schema:about of	named entity 'HIV-1' covid:arg/0491da5ae5c2fa38824350bde5462ed82ebc24e7 named entity 'humoral immunity' named entity 'vaccines' named entity 'multiple' named entity 'virus' named entity 'gp120' named entity 'combinations' named entity 'fourteen' named entity 'hamsters' named entity 'proteins' named entity 'immunogenicity' named entity 'HIV-1' named entity 'gp120' named entity 'virus' named entity 'epitopes' named entity 'wild type' named entity 'Immunogenicity' named entity 'Background' named entity 'HIV-1' named entity 'RPMI 1640' named entity 'gp120' named entity 'gp120' named entity 'phylogenetic' named entity 'Finland' named entity 'Recombinant' named entity 'gp120' named entity 'pseudovirus' named entity 'gp120' named entity 'recombinant protein' named entity 'Hamilton, MT' named entity 'immunogen' named entity 'transfected' named entity 'production of recombinant proteins' named entity 'point mutations' named entity 'HIV virus' named entity 'cell lines' named entity 'HIV' named entity 'amino acid sequences' named entity 'vaccine' named entity 'recombinant proteins' named entity 'HIV-1' named entity 'CHO' named entity 'HIV-1' named entity 'Env' named entity 'sequence database' named entity 'gp120' named entity 'cloned' named entity 'antibodies' named entity 'plasmid' named entity 'control group' named entity 'genetic differences' named entity 'antibody' named entity 'Antibody' named entity 'HIV-1' named entity 'gp120' named entity 'neutralizing antibody' named entity 'immunogenicity' named entity 'HIV-1' named entity 'cross-reactivity' named entity 'HIV-1' named entity 'plasma' named entity 'Hamster' named entity 'HIV' named entity 'antibody response' named entity 'phylogenetic tree' named entity 'CHO' named entity 'myc' named entity 'vectors' named entity 'glycosylation pattern' named entity 'carbohydrates' named entity 'envelope proteins' named entity 'completely sequenced' named entity 'vaccine against HIV' named entity 'antigenic variation' named entity 'CD4+T cells' named entity 'gp120'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software